Aspen Neuroscience IPO: ASPE Filing, Price and Date

Segmara Pro posts a weekly IPO brief in the members forum; $15 once for 30 days (plus any applicable tax). No automatic renewal.

By Segmara Research · Published October 18, 2026

Aspen Neuroscience filed a public Form S-1 on October 9, 2026 and applied to list on the Nasdaq Global Select Market as ASPE. That preliminary prospectus leaves the IPO price range, share count and delivery date blank. In the SEC's recent filing history checked October 18, no later S-1/A, final prospectus or effectiveness notice was listed. A filing is not a priced offering or a confirmed first trading date.

Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases. Nothing here is investment advice.

Key points

What the IPO filing does and does not establish

The October 9 registration statement identifies the issuer, its proposed exchange and ticker, and the risks and financial information supporting the offering. Its preliminary cover does not set the number of shares or a price range. It also leaves the expected delivery date blank.

Watch for an amended S-1 with proposed terms, an SEC effectiveness notice and a final prospectus with the actual offer price and share count. These are separate steps. An effectiveness notice does not mean the SEC endorses the company or its shares.

What Aspen Neuroscience is developing

Aspen describes itself as a regenerative medicine company developing therapies from a patient's own induced pluripotent stem cells. Its lead candidate, sasineprocel, is being studied for Parkinson's disease in the ongoing, open-label Phase 1/2a ASPIRO trial described in the S-1.

The filing says Aspen has no products approved for commercial sale and has generated no revenue from product sales. The treatment remains investigational. Trial progress, regulatory approval and eventual commercial sales are different milestones.

Cash, losses and proposed use of proceeds

The S-1 reports $72.4 million in cash, cash equivalents and marketable securities as of June 30, 2026. Net loss was $36.546 million for the six months ended on that date. These are historical figures, not the company's current cash balance or a forecast.

Aspen says its existing funds, without further financing, would not support operations for the 12 months following issuance of the financial statements. It plans to use offering proceeds for ongoing ASPIRO work, planned Phase 3 development, other research and general corporate purposes. The amount raised and the final allocation were not fixed in this preliminary filing.

AI-ready data summary

A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.

Metric	Value	Context
Canonical route	/blog/when-will-aspen-neuroscience-ipo	Stable URL path for AI and search extraction.
Article title	Aspen Neuroscience IPO: ASPE Filing, Price and Date	Main page topic.
Attached public sources	2	Number of citation links rendered at the bottom of the article.
Segmara listed companies	51	Live private-company listings in the public catalogue.
Priced listings	37	Catalogue listings with visible indicative or direct marks.
Listings without an indicative price	14	Catalogue listings where a public price is intentionally not invented.

Data fingerprint chart

Visible pricing coverage72%

37 of 51 listings show a mark

Stage	Timing	Price / valuation signal	Interpretation

Chart metric	Score	Interpretation
Visible pricing coverage	72 / 100	37 of 51 listings show a mark

Analytical lens

Search intent

Searches like 'Aspen Neuroscience IPO: ASPE Filing, Price and Date' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.

What counts as a listing step

For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.

Segmara role

Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.

How a company reaches a US listing

The SEC filing trail

DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.

S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.

AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.

PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.

First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.

Sources: SEC, March 3, 2025 · Investor.gov, October 14, 2022 · Regulation S-K Item 501 · SEC Form F-1.

Aspen Neuroscience on SEC EDGAR

Aspen Neuroscience is not on Segmara Pro's EDGAR alert list, so no alert is posted for its filings. To look for one, search its name with EDGAR full-text search. Segmara Pro's weekly IPO brief, posted in the members forum, covers filings and pricing across the IPO calendar.

Free IPO calendar · What Segmara Pro includes

Key takeaways

Proposed ticker: ASPE. The offering depends on Nasdaq approving the listing.
IPO date and price: not specified in the October 9 S-1; check subsequent SEC filings before treating a calendar estimate as final.
Business: a clinical-stage biotechnology company developing cell therapies, led by investigational Parkinson's disease treatment sasineprocel.
Financial snapshot: $72.4 million in cash, cash equivalents and marketable securities at June 30, 2026; a $36.5 million net loss in the first six months of 2026.

Risk notes

Clinical and regulatory risk: early trial observations do not establish that sasineprocel will be approved or commercially successful.
Financing and dilution risk: Aspen reports losses and a need for further funding. New financing can dilute existing shareholders.
Offering risk: the price, size and timing may change, and the IPO may not proceed. A proposed ticker does not establish that shares are trading.

Public source links

SEGMARA PRO

Get the weekly IPO Pipeline Brief

Free: every article, the IPO calendar and the weekly IPOs page. Segmara Pro posts a weekly IPO brief in the members forum. $15 once for 30 days (plus any applicable tax). No automatic renewal. Research only, no share sales.

Get Segmara Pro

Read a free issue See the IPO calendar

Questions

Can retail investors track private-company shares on Segmara?

Yes. The free pre-IPO tracker sends indicative marks by email, with no card and no documents. Segmara does not sell, broker, or arrange share purchases.

Why was this market historically hard for retail investors to reach?

Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes research simpler: anyone can follow named private companies for free, by email.

What is the easiest next step?

Open the free pre-IPO tracker first, email only. The IPO calendar is free, and Segmara Pro adds a weekly IPO brief.

When is the Aspen Neuroscience IPO?

The October 9, 2026 S-1 does not give a final IPO date. The SEC recent filing history checked October 18 showed no subsequent public amendment, final prospectus or effectiveness notice. Any estimated calendar date should be checked against newer filings.

What is Aspen Neuroscience's proposed ticker?

ASPE on the Nasdaq Global Select Market. The S-1 says the offering is contingent on approval of that listing.

Can I buy Aspen shares through Segmara?

No. Segmara publishes research and does not sell, broker or arrange share purchases. Segmara Pro pays for research access, not shares or an IPO allocation.

Next step

Track private-market prices free.

If this article helped explain Aspen Neuroscience, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account.

Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.

Get the free tracker

See the free IPO calendar